Spero Therapeutics (STU:2HA) EV-to-Revenue : 0.00 (As of Jun. 05, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Spero Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Spero Therapeutics's enterprise value is €0.16 Mil. Spero Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was €92.37 Mil. Therefore, Spero Therapeutics's EV-to-Revenue for today is 0.00.

The historical rank and industry rank for Spero Therapeutics's EV-to-Revenue or its related term are showing as below:

During the past 9 years, the highest EV-to-Revenue of Spero Therapeutics was 1720.37. The lowest was -447.84. And the median was 0.09.

STU:2HA's EV-to-Revenue is not ranked ^*
in the Biotechnology industry.
Industry Median: 7.985
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-05), Spero Therapeutics's stock price is €1.266. Spero Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €1.72. Therefore, Spero Therapeutics's PS Ratio for today is 0.74.

Spero Therapeutics EV-to-Revenue Historical Data

The historical data trend for Spero Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spero Therapeutics EV-to-Revenue Chart

Spero Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

22.80

1,737.57

123.63

-0.24

0.07

Spero Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-Revenue	Get a 7-Day Free Trial															-0.28	0.09	-0.33	0.07	0.16

Competitive Comparison of Spero Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, Spero Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spero Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spero Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Spero Therapeutics's EV-to-Revenue falls into.

Spero Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Spero Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	0.159	/	92.368
	=	0.00

Spero Therapeutics's current Enterprise Value is €0.16 Mil.
Spero Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €92.37 Mil.

Spero Therapeutics (STU:2HA) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Spero Therapeutics's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	1.266	/	1.718
	=	0.74

Spero Therapeutics's share price for today is €1.266.
Spero Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.72.

Spero Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Spero Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Spero Therapeutics (STU:2HA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spero Therapeutics Inc (STU:2HA) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

SPRO:USA

Address

675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139

Website

https://www.sperotherapeutics.com

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Spero Therapeutics (STU:2HA) Headlines

No Headlines